Browse
Submit Data
Databases
API
Help

Dataset Information

23 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.

ABSTRACT: TRIAL REGISTRATION:ClinicalTrials.gov Identifier: NCT00203502.

SUBMITTER: Hsu PC

PROVIDER: S-EPMC7162481 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.

Hsu Ping-Ching PC Kadlubar Susan A SA Siegel Eric R ER Rogers Lora J LJ Todorova Valentina K VK Su L Joseph LJ Makhoul Issam I

PloS one 20200416 4

<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT00203502. ...[more]

PMID: 32298288

Similar Datasets

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy.

Project description: Not available

| S-EPMC7475504 | biostudies-literature

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

Project description:Triple negative breast cancer is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study was to explore the clinical relevance of Lehmann triple negative breast cancer subtypes by identifying any differences in response to neoadjuvant chemotherapy among them.

2017-11-17 | GSE106977 | GEO

Radiation induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients

Project description:Purpose:The identification of biomarkers predictive of neoadjuvant chemotherapy response in breast cancer patients would be an important advancement in personalized cancer therapy. We hypothesized that due to similarities between radiation and chemotherapy induced cellular response mechanisms, radiation responsive genes may be useful in predicting response to neoadjuvant chemotherapy. Materials and Methods: Murine p53 null breast cancer cell lines representative of the luminal, basal-like and claudin-low human breast cancer subtypes were irradiated to identify radiation responsive genes. These murine radiation induced genes were then converted to their human orthologs. These genes were then used to develop a predictor of pathologic complete response (pCR) that was validated on two independent published neoadjuvant chemotherapy data sets of genomic data with response. Results: A radiation induced gene signature consisting of 30 genes was identified on a training set of 337 human primary breast cancer tumor samples that was prognostic for survival. Mean expression of this signature was calculated for individual samples in two independent published datasets and was found to be significantly predictive of pathologic complete response. Multivariate logistic regression analysis in both independent datasets showed that this 30 gene signature added significant predictive information independent of that provided by standard clinical predictors and other gene expression based predictors of pathologic complete response. Conclusion: This study provides new biologic information regarding response to neoadjuvant chemotherapy and a means of possibly improving the prediction of pathologic complete response. reference x sample

2015-01-21 | E-GEOD-48073 | biostudies-arrayexpress

Project description: Not available

| S-EPMC4004621 | biostudies-literature

Radiation induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients

2015-01-21 | GSE48073 | GEO

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.

Project description: Not available

| S-EPMC5995183 | biostudies-literature

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy.

Project description: Not available

| S-EPMC4819747 | biostudies-literature

Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report.